Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01018810 · ClinicalTrials.gov registry record · Phase 2
A Study for Adults With Plaque Psoriasis
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01018810: Clinical Trial Phase 2 study, sponsored by Eli Lilly and Company.
NCT01018810 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01018810, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
In this study, we will evaluate clinical activity, safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of 5 LY2525623 dosing groups compared to placebo in adults with plaque psoriasis.
Primary Outcome
PASI combines extent of body-surface involvement assessments in 4 anatomical regions and severity of regional desquamation, erythema, and plaque induration/infiltration. Overall score: 0 (no psoriasis) to 72 (severe disease). Study BDAD was terminated after enrolling only 8 patients. Given the small sample size overall and per treatment arm, numerical summaries and statistical comparisons are not appropriate and may be scientifically/clinically misleading; therefore, this outcome measure was not
Interventions
- DRUG LY2525623 Intravenous
- DRUG LY2525623 Subcutaneous
- DRUG Placebo Intravenous
- DRUG Placebo Subcutaneous
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2009-12 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Why NCT01018810 stopped before completion
NCT01018810 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 4 interventions - of which LY2525623 Intravenous is the first listed.
NCT01018810 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01018810 about?
NCT01018810 is a clinical study titled "A Study for Adults With Plaque Psoriasis". In this study, we will evaluate clinical activity, safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of 5 LY2525623 dosing groups compared to placebo in adults with plaque psoriasis.
What is the current status of trial NCT01018810?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2009-12. Estimated completion is 2010-08.
What interventions are being tested in trial NCT01018810?
The interventions under investigation include: LY2525623 Intravenous (DRUG), LY2525623 Subcutaneous (DRUG), Placebo Intravenous (DRUG), Placebo Subcutaneous (DRUG).
Who is sponsoring clinical trial NCT01018810?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01018810's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia